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Introduction: The objective of the study was to describe the pharmacokinetics (PK) of fluconazole, anidulafungin,
and caspofungin in critically ill patients and to compare with previously published data. We also sought to
determine whether contemporary fluconazole doses achieved PK/pharmacodynamic (PD; PK/PD) targets in this
cohort of intensive care unit patients.
Methods: The Defining Antibiotic Levels in Intensive care unit patients (DALI) study was a prospective, multicenter
point-prevalence PK study. Sixty-eight intensive care units across Europe participated. Inclusion criteria were met by
critically ill patients administered fluconazole (n = 15), anidulafungin (n = 9), and caspofungin (n = 7). Three blood
samples (peak, mid-dose, and trough) were collected for PK/PD analysis. PK analysis was performed by using a
noncompartmental approach.
Results: The mean age, weight, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores of the
included patients were 58 years, 84 kg, and 22, respectively. Fluconazole, caspofungin, and anidulafungin showed
large interindividual variability in this study. In patients receiving fluconazole, 33% did not attain the PK/PD target,
ratio of free drug area under the concentration-time curve from 0 to 24 hours to minimum inhibitory concentration
(fAUC0–24/MIC) ≥100. The fluconazole dose, described in milligrams per kilogram, was found to be significantly
associated with achievement of fAUC0–24/MIC ≥100 (P = 0.0003).
Conclusions: Considerable interindividual variability was observed for fluconazole, anidulafungin, and caspofungin.
A large proportion of the patients (33%) receiving fluconazole did not attain the PK/PD target, which might be
related to inadequate dosing. For anidulafungin and caspofungin, dose optimization also appears necessary to
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The epidemiology of invasive fungal infections (IFIs) in
intensive care units (ICUs) is shifting away from those
patients traditionally considered at risk because of ad-
vances in diagnostic and therapeutic interventions [1].
Candida spp. are the third leading cause of infections in
ICUs globally, accounting for up to 90% of all fungal in-
fections [2]. C. albicans is still the leading cause of fun-
gal infections in ICUs, accounting for 40% to 60% of all
invasive Candida infections [3]. However, over recent
decades, the incidence of C. albicans infections has
decreased, with a relative increase in non-albicans Can-
dida spp. infections, with further geographic variations
also present [3,4]. In the critically ill, invasive Candida
spp. infections are associated with high crude and attrib-
utable mortalities as high as 60% and 40%, respectively
[1]. In contrast to Candida spp. infections, the incidence
of Aspergillus spp. infections ranges from 0.3% to 6.9%
in ICU patients and accounts for up to 7% of all fungal
infections. Although the incidence is not as high as that
of Candida spp. infections, invasive aspergillosis is a
debilitating infection with mortality rates as high as 90%
being reported [5].
Fluconazole and echinocandins are the most com-
monly used antifungal agents in ICUs for invasive fungal
infections. Therapeutic preference of these antifungal
agents often depends on the local epidemiology, type of
therapy (prophylaxis, empiric, preemptive, or definitive)
and clinical status of the patient. Fluconazole is recom-
mended for prophylaxis against invasive candidiasis in
ICU patients with abdominal surgery, recurrent gastro-
intestinal perforations, or anastomotic leakages. It is also
recommended for the treatment of candidemia in less
critically ill patients (Acute Physiology and Chronic
Health Evaluation (APACHE) II score <15) without re-
cent exposure to azole antifungal agents [6,7]. Fluconazole
exhibits concentration- and time-dependent antifungal ac-
tivity with a prolonged post-antifungal effect. In line with
this, the ratio of free drug area under the concentration-
time curve from 0 to 24 hours to minimum inhibitory
concentration (fAUC0–24/MIC) is considered the predict-
ive pharmacokinetic (PK)/pharmacodynamic (PD; PK/PD)
index associated with maximal fungal killing. An fAUC0–
24/MIC of at least 100 is associated with fungicidal activity
and optimal outcomes in the clinical setting, especially
when treating immunocompromised or critically ill
patients [8].
The addition of echinocandins (for example, anidula-
fungin and caspofungin) to the antifungal armamentar-
ium was an important step forward in the treatment of
invasive candidiasis, considering the increasing preva-
lence of non-albicans Candida spp. infections, especially
C. glabrata, resistant to fluconazole. Echinocandins are
recommended as a first-line treatment option for invasiveCandida spp. infections in hemodynamically unstable
nonneutropenic patients with prior exposure to azoles
[6,7]. Antifungal activity of echinocandins has been corre-
lated with both ratio of peak plasma concentration to MIC
(Cmax/MIC) and AUC0–24/MIC [9]. However, to date, a
robust PK/PD index for anidulafungin and caspofungin
relating exposure to response is yet to be identified in
clinical studies.
Inadequate initial antifungal dosing contributes not
only to suboptimal outcomes [10-12] but also to the
emergence of resistance [13]. In addition, critically ill pa-
tients tend to have an array of pathophysiological changes
that can cause antifungal PK alterations, potentially lead-
ing to subtherapeutic exposures [14]. Thus, doses estab-
lished based on the experience from other patient cohorts
may not always be optimal to treat patients in ICU, as
evidenced for antibacterial agents [15]. Therefore, it is
important to understand the disposition of the frequently
used antifungal agents like fluconazole, anidulafungin, and
caspofungin in critically ill patients.
The objective of the study was to describe the PK of
fluconazole, anidulafungin, and caspofungin in critically
ill patients and to compare with previously published
data. We also sought to determine whether contempor-
ary fluconazole doses achieve PK/PD target in this
cohort of ICU patients.
Methods
Study design
The Defining Antibiotic Levels in Intensive care unit pa-
tients (DALI) study was a prospective, multicenter PK
point-prevalence study. The protocol has been published
in detail previously [16], and the participating investiga-
tors are listed in Additional file 1). The antifungal agents
that were included in the DALI Study were fluconazole,
anidulafungin, and caspofungin.
Study population
All ICU patients at participating sites were screened, and
eligible patients were identified for participation in the
study by the clinical staff on the Monday of the nominated
week. Subsequently, blood sampling and data collection
occurred throughout the nominated week. The lead site
was The University of Queensland, Australia, with ethical
approval granted by the Medical Research Ethics Commit-
tee (Number 201100283, May 2011). All participating cen-
ters in the DALI Study obtained ethics approval from their
respective ethics committees (Additional file 2). Informed
consent was obtained for each eligible patient.
Drug administration and sample collection
The choice of antifungal agent and dosing was at the
discretion of the treating clinician. Each patient had
three blood samples taken: blood sample A was a peak
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venous infusion; blood sample B was a mid-dose blood
sample taken 50% of the way through a dosing interval;
and blood sample C was a pre-dose concentration taken
at the end of a dosing interval (within 30 minutes of the
next dose).
Blood samples were processed and stored per protocol
to maintain sample integrity. A commercial courier com-
pany transported the clinical samples on dry ice to the
coordinating center (Burns, Trauma and Critical Care
Research Centre, The University of Queensland, Australia).
Data collection
Data collection was performed by trained staff at each
participating center and entered into a case report form.
Various demographic and clinical data were collected,
including age, gender, height, weight, admission diagno-
sis, presence of extracorporeal circuits (for example,
renal replacement therapy), clinical outcome of infec-
tion, and mortality at 30 days. A positive clinical out-
come of therapy was defined as completion of treatment
course without change or addition of antifungal therapy
and with no additional antifungals commenced within
48 hours of discontinuation of the therapy, and if the
outcome of therapy could not be judged for any reason,
it was recorded as indeterminate. Also, organ-function
data (including renal function: serum creatinine concen-
tration during studied dosing interval; 24-hour measured
urinary creatinine clearance (CrCL) (where available),
antibiotic dosing (dose and frequency, time of dosing
and sampling, day of antibiotic therapy), and infection
data (including known or presumed pathogen and patho-
gen MIC) were collected.
Antibiotic dosing data including the dose (in milli-
grams and in milligrams per kilogram total body weight),
infusion duration, frequency of administration, the time
of dosing and sampling, and the day of antibiotic therapy
were collected. All data were collated by the coordinat-
ing center.
Sample analysis
Anidulafungin (0.5 to 0 μg/ml), caspofungin (0.1 to
20 μg/ml), and fluconazole (0.2 to 20 μg/ml) were mea-
sured in plasma by separate validated UHPLC-MS/MS
methods on a Shimadzu Nexera system coupled to a
Shimadzu 8030+ triple quadrupole mass spectrometer
(Shimadzu Corporation, Nakagyo-ku, Kyoto, Japan). The
stationary phase was a Kinetex C8 (50 × 2.10 mm,
1.7 μm) UHPLC column (Phenomenex, Torrance, CA,
USA). The mobile phase was a gradient of acetonitrile
and 0.1% formic acid (anidulafungin and caspofungin) or
acetonitrile and 0.1% formic acid with 10 mM ammonium
formate (fluconazole). Ionization was by positive-mode
electrospray, with analytes detected at the following MRMs:1140.4→ 343.10 (anidulafungin), 1,093.50→ 1,033.50
(caspofungin), 306.7→ 238.2 (fluconazole), 470.10→
160.20 (dicloxacillin), and 350.0→ 281.1 (voriconazole).
Plasma (100 μl) was spiked with internal standard (dicloxa-
cillin for anidulafungin/caspofungin, and voriconazole for
fluconazole) and treated with acetonitrile to precipitate
proteins before instrumental analysis.
For anidulafungin analysis, the supernatant was washed
with dichloromethane to remove lipid-soluble compo-
nents. Sample analysis met batch acceptance criteria. The
methods were validated for linearity, LLOQ, matrix effects,
precision and accuracy, and stock stability by using the
FDA criteria for bioanalysis [17].
PK analysis
The PK parameters for each drug were estimated by
using noncompartmental methods. The apparent ter-
minal elimination-rate constant (kel) was determined
from log-linear least-squares regression. The minimum
and the peak concentration for the dosing period (Cmin
and Cmax) were the observed values. Half-life (T1/2) was
calculated as ln (2)/kel. The area under the concentration-
time curve from 0 to 24 hours (AUC0–24) was calculated
by using the linear trapezoidal approximation. The area
under the plasma concentration–time curve from time 0
to infinity (AUC0–inf ) was calculated by the log-linear
trapezoidal rule until the time of last quantifiable plasma
concentration and then extrapolated to infinity by using
the quotient of the last measurable concentration to the
terminal phase rate constant (kel). The AUC from 0 to
24 hours (AUC0–24) was calculated by using a doubling of
AUC0–12, assuming steady state when fluconazole was ad-
ministered every 12 hours. Clearance (CL) was calculated
by using the equation Dose/AUC0-∞. Protein binding of
fluconazole was assumed to be 12 to determine free
AUC0–24 (fAUC0–24) [18]. For fluconazole, fAUC0–24/MIC
of at least 100 was chosen as the target PK/PD index
associated with efficacy [8].
Results
Fluconazole
Fluconazole blood samples were collected from 26 ICU
patients. Eleven patients were excluded, as the PK pa-
rameters or fAUC0–24/MIC could not be estimated from
the available data. As such, the study sample consisted
of 15 patients from 12 ICUs in six countries (Belgium,
Finland, France, Greece, Portugal, and Turkey). In 67%
of the patients, fluconazole samples were collected at
least 5 days post-initiation of treatment. Measured CrCL
was available for only 10 patients. Demographic and
clinical data, including disease severity and CrCL, are
described in Table 1. C. albicans was isolated from six
patients, of whom MIC was reported in one case (MIC =
0.75 mg/L), C. glabrata was isolated from one patient, and
Table 1 Demographics, clinical characteristics, and dose in critically ill patients receiving fluconazole, anidulafungin,
and caspofungin therapy
Fluconazole Anidulafungin Caspofungin
Number of patients 15 9 6
Age (years) 56 (44–82) 51 (41–66) 62 (58–72)
Weight (kg) 82 (80–90) 81 (76–92) 80 (75–85)
Male sex 11 (73) 7 (78) 5 (71)
Dose received (mg) 400 (200–400) 100 70 (loading dose)
Dose (mg/kg) 4.9 (2.3–5.0) NA NA
APACHE II score 22 (10–30) 18 (15–32) 22 (20–26)
SOFA score 7 (5–9) 6 (3–7) 3 (2–8)
Serum creatinine concentration (mΜ) 88 (64–203) 119 (47–228) 258 (117–286)
Measured creatinine clearance (ml/min) 45 (14–103) 62 (15–113) NA
Data are described as median [1st to 3rd quartile] or n (%).
APACHE, Acute Physiology and Chronic Health Evaluation II score; SOFA, sequential Organ Failure Assessment; NA, insufficient patients with measured creatinine
clearance/not applicable.
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isolated. Of patients administered fluconazole, 27% (n = 4)
achieved a positive clinical outcome, with clinical outcome
described as indeterminate in 40% (n = 6) of patients; 47%
(n = 7) of patients had died by day 30.
As shown in Table 1, fluconazole median dose was
400 mg (4.9 mg/kg). The observed fluconazole AUC0–24,
Cmax, and Cmin in comparison with other studies is pre-
sented in Table 2. The target fAUC0–24/MIC ≥100 was
reached in 86% of patients when the assumed MIC was
1 mg/L. If MIC 2 mg/L (clinical breakpoint) and 4 mg/L
(clinical breakpoint for resistance by using EUCAST
methods and susceptible dose-dependent by using CLSI
methods) were used, then the target fAUC0–24/MIC ≥100
was reached in 67% and 13% of patients, respectively. As
expected, dose was found to be significantly associated
with the achievement of fAUC0–24/MIC ≥100 (n = 15, P =
0.0003) (Figure 1). The median dose received in patients
with fAUC0–24/MIC ≥100 was 5 mg/kg compared with
2 mg/kg in patients with fAUC0–24/MIC <100. Only two
(20%) patients, both with CrCL < 50 ml/min, received the
recommended weight-based fluconazole dose and both
attained the target exposure. No difference was observedTable 2 Comparison of exposures achieved in this study with
Anidulafungin Caspofungin
Parameter This study
(ICU patients)
Liu et al. [25]
(ICU patients)
Liu et al. [25]
(healthy
volunteers)
This study
(ICU patients)
AUC0–24 55 (28) 93.0 (41) 105.0 (22) 52.0 (53)
Cmax 3.9 (29) 7.7 (56) 7.0 (22) 3.9 (55)
Cmin 1.8 (30) 3.0 (44) 3.1 (25) 1.5 (57)
aMean (95% CI); bMean (SD). AUC0–24, area under the concentration-time curve from
concentration; CV, coefficient of variation; ICU, intensive care unit.in daily doses between patients with CrCL <50 ml/min
(median (1st to 3rd quartile) to 2.3 (1.7 to 5.0) mg/kg) and
with CrCL >50 ml/min (4.4 (1.8 to 5.0) mg/kg) (P = 0.65).
Anidulafungin and caspofungin
Anidulafungin blood samples were collected from 10 ICU
patients, with one patient excluded as PK parameters
could not be estimated from available data. As such, the
study sample consisted of nine patients from seven ICUs
of three countries (Spain, Italy, and Greece). Caspofungin
blood samples were collected from seven patients from six
ICUs of five countries (Belgium, France, Greece, Italy, and
Portugal). Demographic data, disease severity, and renal
function are described in Table 1. C. albicans was the iso-
lated pathogen in the majority of the cases (six patients),
with Aspergillus spp. isolated from two patients receiving
caspofungin. In terms of clinical outcome for the anidula-
fungin patients, 67% (n = 6) were defined to have achieved
a positive clinical outcome, and 33% (n = 3) had an inde-
terminate clinical outcome. For the caspofungin patients,
43% (n = 3), achieved a positive clinical outcome, and 11%
(n = 3) had an indeterminate clinical outcome. The 30-day
mortality was 11 (n = 1) and 29% (n = 2) for the patientsother studies (mean (%CV))
Fluconazole
Wurthwein
et al. [26]
(general
patients)
Stone
et al. [27]a
(healthy
volunteers)
This studyb
(ICU patients)
Buijk
et al. [23]a
(surgical
patients)
Sobue
et al. [24]b
(Healthy
volunteers,
800 mg)
170.0 (34) 97.0 (87–109) 359 (259) 409 (336–482) 608 (118)
13.8 (31) 12.1 (11–13) 20 (14) 25 (22–28) 34 (6)
4.2 (2.56) 1.4 (1.1–1.8) 14 (11) 15 (10–20) 20 (NR)
0 to 24 hours Cmax, observed maximum concentration; Cmin, observed minimum
Figure 1 The box plot of fluconazole dose in milligrams per
kilogram stratified by the patients achieving and not achieving
the PK/PD index, free drug area under the concentration-time
curve from 0 to 24 hours (fAUC0–24/MIC).
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The observed anidulafungin and caspofungin AUC0–24,
Cmax, and Cmin in comparison to other studies are pre-
sented in Table 2.
Discussion
This is the first multinational multicenter point-
prevalence study reporting PK variability of fluconazole,
anidulafungin, and caspofungin, and PK/PD target at-
tainment of fluconazole in critically ill patients. This
study demonstrated that 33% of patients receiving flu-
conazole did not achieve the desired PK/PD index re-
quired for optimal outcome. In light of the increasing
information on the antifungal exposure/response rela-
tion [12,19-22], achieving the PK/PD target should be
considered critical to improve the patient outcomes and
to minimize the emergence of fluconazole resistance.
The observed fluconazole AUC0–24, Cmin, and Cmax
were comparable to values previously reported in surgi-
cal ICU patients [23]. However, variability was higher
compared with healthy volunteers (Table 2) [24]. This
may be attributed to underlying pathophysiological
changes that occur in ICU patients. The observed anidu-
lafungin variability in AUC0–24, Cmin, and Cmax was not
as high as observed in the study by Liu et al. [25], who
recruited a larger cohort of surgical ICU patients but
was higher than variability observed in healthy volun-
teers (Table 2) [25]. The PK parameter estimates were
also lower than those observed by Liu et al. [25]. The
patient cohort in our study were younger (60 vs. 51 yrs)
with a higher median weight (65 vs. 81 kg) compared to
the cohort in the study by Liu et al. [25]. It is possible
that the increased clearance associated with these differ-
ences may explain the lower exposures observed in this
study, although these postulates are yet to be proven foranidulafungin. For caspofungin, the observed variability
was higher than that reported in patients with invasive
aspergillosis with lower exposures compared with inva-
sive aspergillosis patients and healthy volunteers [26,27]
(Table 2). However, the Cmin observed in the current
study was comparable to that observed by Nguyen et al.
[28] in surgical ICU patients with large variability (0.5 to
4.1 mg/L versus 0.5 to 2.6 mg/L, in this study). The
reasons for lower exposures observed for caspofungin in
our study may be two-fold – firstly, 70% of patients were
sampled on day 1 and secondly, our patient cohort was
critically ill compared to surgical patients and patients
with invasive aspergillosis in other studies [27,29]. Shock
in particular may be a strong factor given that in an
experimental shock model in pigs, a 25% reduction in
AUC was observed during the initial shock phase [30].
An important observation from this study was the
variation in doses of fluconazole used (Table 1). In par-
ticular, use of a “standard” 400-mg daily dose was com-
mon, which when converted to a mg/kg dose, commonly
fell below the 6 mg/kg recommended dose [7] (with
12 mg/kg loading dose), which was then associated with
not achieving the PK/PD target (Figure 1). Although a
50% dose reduction is recommended in patients with
CrCL <50 ml/min [29], neither these patients with renal
dysfunction nor those with normal renal function had a
median dose in line with the recommended dose. Of note,
only two (20%) patients, both with CrCL <50 ml/min,
received the recommended weight-based fluconazole dose,
and both attained the target exposure. Our data support
observations from previous studies, which have demon-
strated that suboptimal dosing with fluconazole is preva-
lent [30]. Moreover, as shown in Figure 1, a clear
association exists between the mg/kg dose administered
and attainment of a PK/PD target supporting individual-
ized weight-based dosing. Indeed, the use of the standard
400-mg dose appears to result in suboptimal exposure,
suggesting that a “one dose fits all” approach for flucona-
zole is flawed. It follows that in some patients with higher
body weight, doses higher than the standard 400 mg are
required. In line with this, the use of loading doses may
help the early achievement of PK/PD targets for flucona-
zole. Toxicity concerns should not dissuade clinicians
from more-aggressive doses because fluconazole is a very-
well-tolerated drug with much higher doses successfully
used without adverse effects [31].
We could not attempt to determine the PK/PD target
attainment for anidulafungin and caspofungin, as the
PK/PD targets relating exposure to clinical response are
yet to be defined, and data from animal studies were
found to be highly variable.
Some limitations of this study were found. First, al-
though many ICUs were included in the study, the num-
ber of recruited patients was not comprehensive, and
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ability in the population. Despite this, the recruitment of
patients from many different ICUs in different countries
does enhance the generalizability of the results.
Second, we did not measure unbound concentrations
of the antifungals, although it should be noted that pre-
vious studies defining PK/PD targets have also measured
total drug concentrations.
Third, this study used only three concentrations to
estimate PK parameters, although this is likely to be
appropriate, given the relatively long half-life of these
drugs. Finally, we used breakpoint MICs determined
by EUCAST and CLSI to estimate fluconazole PK/PD
targets because of the lack of reported actual MICs for a
large proportion of patients.
Conclusion
This study demonstrated that contemporary dosing of
fluconazole causes a significant proportion of patients
not achieving PK/PD targets because of PK variability.
For fluconazole, this appears to be caused by the use of
a fixed-dosing approach (that is, 400 mg daily) rather
than the recommended weight-based dosing regimen. In
this study, patients receiving adequate weight-based
doses of fluconazole were more likely to achieve PK/PD
targets. Similarly, a large variability was observed in PK
for anidulafungin and caspofungin. With the limitation
of small sample size, this study illustrates that antifungal
dosing in the critically ill is as complex as previously
demonstrated for antibiotics. Further research is required
to optimize exposures of antifungal agents and thus
potentially to improve clinical outcomes associated with
antifungal use in critically ill patients.
Key messages
 We have described pharmacokinetic variability of
fluconazole, anidulafungin, and caspofungin and PK/PD
target attainment of fluconazole in critically ill patients.
 Considerable interindividual variability was observed
for fluconazole, anidulafungin, and caspofungin. In
anidulafungin and caspofungin, observed exposures
were lower than those observed in other ICU
studies and patient cohorts.
 Suboptimal dosing with fluconazole is prevalen; 33% of
patients receiving fluconazole did not achieve the
desired PK/PD index required for optimal outcome.
Patients receiving adequate weight-based doses (mg/kg)
of fluconazole were more likely to achieve PK/PD
targets
 Toxicity concerns should not dissuade clinicians
from more-aggressive doses because fluconazole is a
very-well-tolerated drug with much higher doses
successfully used without adverse effects. With the limitation of small sample size, this study
illustrates that antifungal dosing in the critically ill is
as complex as previously demonstrated for antibiotics.
Further research is required to optimize exposures of
antifungal agents in at-risk critically ill patients.
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